Psychedelic Drugs Hold Medical Promise: A Summary

The DEA and the U.S. Food and Drug Administration maintain that there is insufficient research to justify recategorization from Schedule I. This stance creates a catch-22 by basing the decision on the need for more research while limiting the ability of scientists to conduct that research. The June report recommends transferring responsibility for drug scheduling from the DEA to another agency or nongovernmental organization without a history of anti-drug bias, such as the U.S. National Academy of Sciences. No matter how it happens, until the drugs are reclassified, bringing psychedelics from research into clinical practice will be an uphill battle.

Source